Breaking
🇺🇸 FDA
Emergent BioSolutions Partners with Substipharm for $34.5M Japanese Encephalitis Vaccine Manufacturing Deal
NewsApr 29, 2026

Emergent BioSolutions Partners with Substipharm for $34.5M Japanese Encephalitis Vaccine Manufacturing Deal

Emergent BioSolutions announces $34.5M partnership with Substipharm Biologics to manufacture IMOJEV Japanese encephalitis vaccine for U.S. government distribution.

James Chen, PharmD
FDA Approves V-Protect Vaccine: Key Details on ViroDefense’s New Tool
NewsEmerging Infectious DiseasesApr 20, 2026

FDA Approves V-Protect Vaccine: Key Details on ViroDefense’s New Tool

ViroDefense's newly approved V-Protect vaccine promises to bolster immunity against viral infections, marking a significant advancement in public health.

Dr. Sarah Mitchell